AngioDynamics, Inc. (NASDAQ: ANGO) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $483M. The Maz Rating grades it against the other companies in its sector.
AngioDynamics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $11.49, AngioDynamics, Inc. trades at 1.5x sales and 2.9x book value. Over the last twelve months it generated about $327M of revenue and a net loss of $33M. It runs a gross margin of 55.7%, an operating margin of -11.2% and a net margin of -10.1%. It shows return on equity of -19.2%, return on invested capital of -19.9% and a free cash flow yield of 0.3%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 2.40. Over the past 52 weeks the share price ranged from $9.39 to $16.29, with a beta of 0.28.
AngioDynamics, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 5 Buy and 6 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of August 2026, AngioDynamics, Inc. (ANGO) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.31% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.87% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.31% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.87% / 33% · Receivables / Mkt Cap (36m) 7.76% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.31% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.87% / 33.33% · Receivables / Mkt Cap (24m) 7.76% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.78% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 16.1% / 33.33% · Receivables / Avg Assets (4Q) 17.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 0.75% / 33.33% · (Cash+ST Inv) / Total Assets 14.0% / 33.33% · (Cash+Recv) / Total Assets 32.6% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
Yes. As of August 2026, AngioDynamics, Inc. (ANGO) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. AngioDynamics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
AngioDynamics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated August 31, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.